---
figid: PMC5881740__jjx00301
figtitle: JAK-STAT signalling pathway
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC5881740
filename: jjx00301.jpg
figlink: /pmc/articles/PMC5881740/figure/F1/
number: F1
caption: The JAK-STAT signalling pathway. Many cytokines important in the pathogenesis
  of inflammatory bowel disease [IBD] signal via the JAK-STAT pathway. Cytokine signalling
  induces phosphorylation of JAKs, which phosphorylate STAT proteins. STAT proteins
  form homo- or heterodimers and migrate into the nucleus where they activate transcription
  of inflammatory cytokines. JAK inhibitors are new therapeutic agents currently being
  investigated in clinical trials in IBD. First-generation JAK inhibitors [e.g. tofacitinib]
  target multiple JAKs, whereas second-generation JAK inhibitors [e.g. filgotinib]
  selectively target one JAK.
papertitle: The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
reftext: L.C.S. De Vries, et al. J Crohns Colitis. 2017 Jul;11(7):885-893.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9619406
figid_alias: PMC5881740__F1
figtype: Figure
redirect_from: /figures/PMC5881740__F1
ndex: 0a739d50-ded9-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5881740__jjx00301.html
  '@type': Dataset
  description: The JAK-STAT signalling pathway. Many cytokines important in the pathogenesis
    of inflammatory bowel disease [IBD] signal via the JAK-STAT pathway. Cytokine
    signalling induces phosphorylation of JAKs, which phosphorylate STAT proteins.
    STAT proteins form homo- or heterodimers and migrate into the nucleus where they
    activate transcription of inflammatory cytokines. JAK inhibitors are new therapeutic
    agents currently being investigated in clinical trials in IBD. First-generation
    JAK inhibitors [e.g. tofacitinib] target multiple JAKs, whereas second-generation
    JAK inhibitors [e.g. filgotinib] selectively target one JAK.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL12A
  - IL12B
  - IFNG
  - IL2
  - IL6
  - IL37
  - IL23A
  - JAK1
  - JAK3
  - TYK2
  - JAK2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - Tofacitinib
---
